Guzmán-Herrera S, Muñoz-Zurita G, Pezzat-Zaid E

Language: Spanish
References: 17
Page: 5-11
PDF size: 386.34 Kb.

ABSTRACT

Introduction. Diabetic neuropathy is defined as the set of morphological and functional alterations of the peripheral nervous system caused by diabetes when no other causes of neuropathy are found. It is estimated that the prevalence and incidence of clinically significant diabetic neuropathy is 60%.
Objective. To determine the management and knowledge of diabetic neuropathy by doctors working in primary care in the Family Medicine Unit No. 2 of the IMSS hospital in the city of Puebla.
Materials and Methods. This was a descriptive, observational, homodemic, prospective cross investigation, with participation by 72 physicians, including 32 Family Medicine physicians and 40 Residents in the Family Medicine Unit No. 2. Participants were given a survey to assess their knowledge about diabetic neuropathy. descriptive
Results. Of the total population surveyed, 59.7% felt that the main involvement of diabetic neuropathy is in the peripheral nervous system, while only 37.5% considered prolonged hyperglycemia as the main risk factor for diabetic neuropathy, and 67% made their diagnoses based on exploration anamnesis and physical exams only, while only 28.1% were aware of tricyclic antidepressants as elective treatments. Only 16% knew of a validated test for the diagnosis of diabetic neuropathy.
Conclusion. Knowledge about diabetic neuropathy in the first level of medical care is limited.

REFERENCES

1. Fernández Travieso Julio C. Manejo de la neuropatía diabética. Revista CENIC Ciencias Biológicas, Vol. 38, No. 1, 2007. Enero-Abril, 20-26.

2. Betancourt JA, Covarrubias GA, Guevara LU. Mecanismos generadores y consideraciones terapéuticas futuras de la polineuropatía diabética dolorosa. Rev Mex Anest 2008;31:28-36.

3. American Diabetes Association. (2014). Standards of medical care in diabetes-2014. Diabetes care, 37, S14.

4. Boulton AJM. Diabetic neuropathy: classification, measurement and treatment. Current Opinion in Endocrinology & Diabetes; 2007. 141-145.

5. Pedraza C. Neuropatías diabéticas formas clínicas y diagnóstico. Rev. Med. Clin. CONDES; 2009. 20 (5) 681-686.

6. ALAD & WORLD WIDE. Guía práctica en el Manejo de la Polineuropatía diabética. NEURALAND. 2010.

7. ACCORD. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med.2008 358:2545-2559.

8. Brian C Callaghan, Hsinlin T Cheng, Catherine L Stables, Andrea L Smith, Eva L Feldman. Diabetic neuropathy: clinical manifestations and current treatments. The Lancet Neurology. June 2012. 521- 534.

9. Curià Casanoves Francisco J. Evidencias en el tratamiento del dolor neuropático. FMC. 2008. 15(9):592-604.

10. Samper Bernal, Monerris Tabasco MM, Homs Riera M. Etiología y manejo de la neuropatía diabética dolorosa. Rev. Soc. Esp. Dolor. 2010. 17(6):286–296.

11. Haanpää Maija, Attal Nadine, Backonja Miroslav, et al. NeuPSIG guidelines on neuropathic pain assessment. PAIN. 152 14–27. 2011

12. Cruccu, Giorgio, and Andrea Truini. “Tools for Assessing Neuropathic Pain.” PLoS Medicine 6.4 (2009): e1000045. [En Linea] [Consultado 1 de Dic. 2013].

13. Fernández Y, Acuna A, Carrabs M. Análisis farmacoeconómico de Carbamazepina, Gabapentina, Pregabalina en el manejo del dolor neuropático. Informe Médico 2009. 11 (6): 335-340.

14. Attal, N, Cruccu, G, Baron, R, Haanpää, M., Hansson, P, Jensen, T. S, et al (2010). EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology, 17(9), 1113-e88.

15. Secretaría de Salud, Guía de Práctica Clínica: Diagnóstico, y tratamiento médico del dolor por neuropatía diabética en adultos en el primer nivel de atención, México: , 2009.

16. Lindsay TJ1, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician. 2010 Jul 15;82(2):151-8.

17. Feldman EL, McCulloch DK. Treatment of diabetic neuropathy. Last reviewed November 2014. UpToDate Inc. Waltham, MAPsychopharmacol Bull 2003;37(4):99-115.